Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra

→  The reverberations continue from Bristol-Myers Squibb’s missteps with Opdivo earlier this year. Shares dropped four percent this week as rumors of a potential sale once again began to swirl, Bloomberg reports.  Immuno-oncology and drug combinations are primary focuses for Bristol-Myers Squibb.

→  Regenera shareholders have offered to buy shares of Alcobra for 66.6% of the combined company. Alcobra is running out of options since it hasn’t recovered from the failure of its ADHD drug in September 2014.

→  The big pharma story today: FDA commissioner Scott Gottlieb has asked Endo to pull its controversial opioid Opana ER from the market. A number of lawmakers have been urging Gottlieb to do something about the opioid epidemic, and this would be his first tangible move on that front.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017